REVIEW ARTICLE Sue Rimes, et al; ONCOLOGY Nurse Edition Vol. 25 No. 10 Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers.
REVIEW ARTICLE John O. Schorge, et al; ONCOLOGY Vol. 25 No. 10 The timing and clinical benefit of a second debulking operation for recurrent disease is contentious. This article focuses on the recent debate regarding when—or whether—patients with ovarian cancer should undergo aggressive surgical resection.
NEWS & ANALYSIS Anna Azvolinsky, PhD Many doctors do not properly adhere to current guidelines for offering breast and ovarian cancer counseling and testing services to their female patients, according to a recent study from the Division of Cancer Prevention and Control at the CDC. The vignette-based national survey finds that while genetic counseling is recommended for women at high risk for breast and/or ovarian cancer, only 41% of physicians self-reported adhering to recommendations to refer for genetic counseling or testing.
REVIEW ARTICLE Maria Jose Echarri Gonzalez, et al;ONCOLOGY Vol. 25 No. 2 This article reviews the known data on the dose-effect relationship for platinum drugs in ovarian cancer, and explores why interest in platinum drugs has become the central focus of ovarian cancer treatment.
CME Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers. •The Complexity of Hereditary Cancer Syndromes
A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?
A 43-year-old woman presented with symptoms of abdominal pain and uterine bleeding. At physical examination, a palpable mass was present in the right lower abdominal quadrant.
A 46-year-old woman presented for medical evaluation due to a 2-month history of increasing difficulty in ambulation, especially getting up out of a chair or climbing stairs. She had also noticed swelling and discoloration of both upper eyelids (as depicted).
A considerable number of women with breast cancer are diagnosed during their reproductive years. In the short period of time in which newly diagnosed women will need to make decisions about surgical options and adjuvant therapy, younger women with breast cancer also face the potential impairment or complete loss of their fertility. More »
A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis? More »
A single-center study analyzed the frequency of breast cancer susceptibility mutations among black women diagnosed with breast cancer. The findings suggest that broader genetic screening may be beneficial for these women. The study also suggests that family history is not the only criteria by which patients at risk for breast cancer can be identified. More »
We speak with two experts to discuss breast cancer risk, genetics, and prevention options available to women at high risk of developing breast and ovarian cancer. More »
Two genome-wide studies have identified a total of 12 new genetic loci associated with a higher risk of testicular cancer. The risk-associated genetic variations could help clinicians single out higher-risk men for screening and early detection. More »
CancerNetwork interviews two prominent ovarian cancer researchers from both sides of the Atlantic on the role of PARP inhibitors and the challenges of developing ovarian cancer therapies.
Key Differences between FQHCs and RHCs Chastity Werner, RHIT, June 13, 2013 FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice Susanne Madden, June 12, 2013 Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices Ericka L. Adler, June 12, 2013 Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
iPad Alternatives for Mobile Physicians Marisa Torrieri, June 11, 2013 As more physicians are seeing the merits of media tablets, the market is expanding, too.
In this review, we discuss the discovery and biologic significance of HE4 and evaluate available evidence regarding the utility of HE4 as a biomarker for ovarian and endometrial cancer.
Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
This article reviews the trials that have been conducted with PARP inhibitors in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and places the impact of those results in the larger context of PARP inhibitor development.
The timing and clinical benefit of a second debulking operation for recurrent disease is contentious. This article focuses on the recent debate regarding when—or whether—patients with ovarian cancer should undergo aggressive surgical resection.
A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?
A 43-year-old woman presented with symptoms of abdominal pain and uterine bleeding. At physical examination, a palpable mass was present in the right lower abdominal quadrant.
A 46-year-old woman presented for medical evaluation due to a 2-month history of increasing difficulty in ambulation, especially getting up out of a chair or climbing stairs. She had also noticed swelling and discoloration of both upper eyelids (as depicted).
CancerNetwork interviews two prominent ovarian cancer researchers from both sides of the Atlantic on the role of PARP inhibitors and the challenges of developing ovarian cancer therapies.
